ArticleCancer medicine2021
HER2 targeting near-infrared photoimmunotherapy for a CDDP-resistant small-cell lung cancer.
Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 20 citations in OpenAlex.
- Recent advances in near-infrared dye conjugates for near-infrared photoimmunotherapy (NIR-PIT): enhancing therapeutic efficacy and immune mechanisms.RSC chemical biology · 2026Review
- Near infrared photo-bacterialflora modulation technology realized controlling periodontitis: modulation of disease-associated dysbiosis in oral microbiota using near infrared photo-antibacterial targeting therapy (NIR-PATJournal of translational medicine · 2026Article
- Metabolotheranostics of pancreatic cancer by targeting choline, glutamine, and glucose transporters with photoimmunotherapy.Npj imaging · 2026Article
- Near Infrared Photoimmunotherapy for Lung Cancer: Recent Development and Perspective.ImmunoTargets and therapy · 2026Review
- Near-infrared photoimmunotherapy for effective elimination of ovarian cancer cells by inducing immunogenic cell death.Molecular therapy. Oncology · 2025Article
- Photoinduced Actin Aggregation Involves Cell Death: A Mechanism of Cancer Cell Cytotoxicity after Near-Infrared Photoimmunotherapy.ACS nano · 2025Article
- Near-infrared photoimmunotherapy: mechanisms, applications, and future perspectives in cancer research.Antibody therapeutics · 2025Review
- Near-infrared photoimmunotherapy in cancer treatment: a bibliometric and visual analysis.Frontiers in pharmacology · 2024Article
- Contrast-enhanced ultrasound imaging for monitoring the efficacy of near-infrared photoimmunotherapy.EBioMedicine · 2023Article
- Recent Advances in Localized Immunomodulation Technology: Application of NIR-PIT toward Clinical Control of the Local Immune System.Pharmaceutics · 2023Review
- Near Infrared Photoimmunotherapy: A Review of Recent Progress and Their Target Molecules for Cancer Therapy.International journal of molecular sciences · 2023Review
- Recent advances in anti-multidrug resistance for nano-drug delivery system.Drug delivery · 2022Review
- Near-infrared-induced drug release from antibody-drug double conjugates exerts a cytotoxic photo-bystander effect.Bioengineering & translational medicine · 2022Article
- Near-Infrared Photoimmunotherapy for Thoracic Cancers: A Translational Perspective.Biomedicines · 2022Review
- Review
- HER2 targeting near-infrared photoimmunotherapy for a CDDP-resistant small-cell lung cancer.Cancer medicine · 2021Article
- Identification of potential cell surface targets in patient-derived cultures toward photoimmunotherapy of high-grade serous ovarian cancer.Photochemistry and photobiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman epidermal growth factor receptor 2 (HER2) is tyrosine kinase receptor that belongs to the ErbB family and is overexpressed on the membrane surface of various cancer cells, including small cell lung cancer (SCLC); however, no HER2 targeted therapy for SCLC have yet been established. Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer therapy based on photo-absorber, IRDye-700DX (IR700), -antibody conjugates, and near-infrared (NIR) light.
methodsWe used HER2-positive SCLC parental cell lines (SBC-3) and its chemoresistant cell lines, and examined therapeutic efficacy of HER2 targeting NIR-PIT using anti HER2 antibody trastuzumab.
resultsWe found that HER2 expression was upregulated on chemoresistant cell lines, especially cisplatin-resistance (SBC-3/CDDP). In vitro, the rate of cell death increased with the amount of NIR-light irradiation, and it was significantly higher in SBC-3/CDDP than in SBC-3. In vivo, tumor growth was more suppressed in SBC-3/CDDP group than in SBC-3 group, and survival period tended to be prolonged.
conclusionIn this study, we demonstrated that HER2 targeting NIR-PIT using trastuzumab is promising therapy for HER2-positive SCLC, and is more effective when HER2 expression is upregulated due to CDDP resistance, suggesting that the HER2 expression level positively corelated with the efficacy of NIR-PIT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.